(Q38790052)

6 September 2017

title

Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016. (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

6 September 2017

1 reference

1 reference

1 reference

Nezam H Afdhal

3

0 references

author name string

Dharmesh H Kaswala

series ordinal

1

1 reference

6 September 2017

Michelle Lai

series ordinal

2

1 reference

6 September 2017

publication date

26 March 2016

1 reference

Digestive Diseases and Sciences

6 September 2017

published in

1 reference

6 September 2017

volume

61

1 reference

6 September 2017

issue

5

1 reference

6 September 2017

page(s)

1356-1364

1 reference

https://scigraph.springernature.com/pub.10.1007/s10620-016-4079-4

6 September 2017

exact match

0 references

cites work

AGA technical review on nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Management of nonalcoholic fatty liver disease: a 60-year-old man with probable nonalcoholic fatty liver disease: weight reduction, liver biopsy, or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

The global NAFLD epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Nonalcoholic Steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Evaluation of liver fibrosis: a concise review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Diagnosis and quantitation of fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Noninvasive assessment of liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: An Enhanced Model of BARD Score.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

APRI and FIB-4 Scores Are Useful After Liver Transplantation Independently of Etiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Liver fibrosis in overweight patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Apoptosis and cytokines in non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Hepatic fibrosis: are any of the serum markers useful?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Contemporary assessment of hepatic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

The utility of radiological imaging in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: a retrospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

CT and MRI of diffuse liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Magnetic resonance elastography for the noninvasive staging of liver fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Utilization of FibroScan in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Diagnosis of hepatic steatosis and fibrosis by transient elastography in asymptomatic healthy individuals: a prospective study of living related potential liver donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Increased liver stiffness in alcoholic liver disease: differentiating fibrosis from steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Acute viral hepatitis increases liver stiffness values measured by transient elastography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Impact of food intake, ultrasound transducer, breathing maneuvers and body position on acoustic radiation force impulse (ARFI) elastometry of the liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Comparison of blood tests for liver fibrosis specific or not to NAFLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Nonalcoholic fatty liver disease: rapid evaluation of liver fat content with in-phase and out-of-phase MR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4079-4

Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions

21 January 2018

1 reference

12 December 2020

Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity

1 reference

12 December 2020

FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice

1 reference

12 December 2020

Liver stiffness is directly influenced by central venous pressure

1 reference

12 December 2020

Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease

1 reference

12 December 2020

ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: a prospective study

1 reference

12 December 2020

Role of liver biopsy in nonalcoholic fatty liver disease

1 reference

12 December 2020

The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease

1 reference

12 December 2020

Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease

1 reference

12 December 2020

Liver biopsy versus noninvasive methods--fibroscan and fibrotest in the diagnosis of non-alcoholic fatty liver disease: a review of the literature

1 reference

12 December 2020

The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

1 reference

12 December 2020

Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease

1 reference

12 December 2020

Prospective evaluation of FibroTest®, FibroMeter®, and HepaScore® for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C

1 reference

12 December 2020

Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis

1 reference

12 December 2020

Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity

1 reference

12 December 2020

Ultrasound scanning in the detection of hepatic fibrosis and steatosis

1 reference

12 December 2020

FibroMeters: a family of blood tests for liver fibrosis

1 reference

12 December 2020

Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease

1 reference

12 December 2020

1 reference

12 December 2020

Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases

1 reference

12 December 2020

Non-invasive assessment of liver fibrosis with impulse elastography: comparison of Supersonic Shear Imaging with ARFI and FibroScan®

1 reference

12 December 2020

TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease

1 reference

12 December 2020

FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest

1 reference

12 December 2020

Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease

1 reference

12 December 2020

Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease

1 reference

12 December 2020

Chronic inflammation in obesity and the metabolic syndrome

1 reference

12 December 2020

10.1007/S10620-016-4079-4

Identifiers

DOI

1 reference

Dimensions Publication ID

6 September 2017

1033663836

0 references

1 reference